<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03222635</url>
  </required_header>
  <id_info>
    <org_study_id>NL6116501817</org_study_id>
    <nct_id>NCT03222635</nct_id>
  </id_info>
  <brief_title>Prospective Endoscopic Follow-up of Patients With Submucosal Esophageal Adenocarcinoma (The PREFER Trial)</brief_title>
  <official_title>Endoscopic Management of Patients With T1bN0M0 Esophageal Adenocarcinoma: a Prospective Multicenter Registry.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this prospective multicenter study is to evaluate the safety of an endoscopic
      follow-up strategy in patients treated with endoscopic resection (ER) for submucosal
      esophageal adenocarcinoma (T1bN0M0 EAC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Traditionally, the risk of lymph node metastasis associated with submucosal EAC was
      considered too high to offer these patients endoscopic follow-up. Only in elderly patients
      with comorbidity, more often an endoscopic protocol is selected. However, the risk of lymph
      node metastasis associated with submucosal EAC is mainly based on surgical series. Recently a
      number of studies, which included patients treated endoscopically, were published indicating
      that the risk of lymph node metastasis may be much lower than generally assumed.Therefore, a
      less invasive and organ preserving approach may not only be an option in the frail and
      elderly, but for all patients with submucosal EAC's.

      Aim of this multicenter study is to prospectively evaluate the safety of endoscopic follow-up
      in patients treated by endoscopic resection for submucosal (T1bN0M0) EAC.

      High-resolution upper endoscopy with white-light endoscopy and narrow-band imaging
      supplemented with an EUS are performed every three months during the first two years after
      ER. After 1 year, a CT-thorax/abdomen will be performed to check for distant metastasis.
      During the third and fourth year of follow-up, EUS and upper endoscopy are performed every
      six months. From the fifth year on, EUS and upper endoscopy are performed annually.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 25, 2017</start_date>
  <completion_date type="Anticipated">July 25, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year disease-specific mortality/survival (descriptive statistics in SPSS, percentages, survival analysis)</measure>
    <time_frame>5 years</time_frame>
    <description>Disease specific mortality is decribed as mortality directly linked to the esophageal adenocarcinoma (i.e., metastasized EAC, metastasized disease with a simultaneously primary cancer present and it cannot be ruled out (based on histology) that the metastases are related to the other primary cancer, death due to complications of the endoscopic procedure, death due to complications after surgery or CRT, no clear cause of death in patients who have metastases or untreated local recurrence). If patients are diagnosed with distant metastases, and subsequently die of a non-tumor related cause, patients will still be documented as tumor-related death. Will be measured in number of patients and percentages. Survival analysis using Kaplan Meier will be performed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (descriptive statistics in SPSS, percentages, survival analysis)</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival of study population (tumor-related + non-tumor-related deaths). Measured in numbers and percentages, survival analysis (KM).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lymph node metastasis, confirmed by cytology and/or histology (descriptive statistics in SPSS, number of patients (%))</measure>
    <time_frame>5 years</time_frame>
    <description>Confirmed by cytology and/or histology by performing FNA during EUS or biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence eligible for endoscopic therapy (descriptive statistics in SPSS, number of patients (%))</measure>
    <time_frame>5 years</time_frame>
    <description>In case a local recurrence is found during FU endoscopy, histopathology have to show if it is recurrent cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence requiring surgical therapy (descriptive statistics in SPSS, number of patients (%))</measure>
    <time_frame>5 years</time_frame>
    <description>In case a local cancer recurrence is not amendable for endoscopic re-treatment, for example due to extensive disease or fibrosis, a patient will be referred for surgery if possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis, histologically proven (descriptive statistics in SPSS, number of patients (%))</measure>
    <time_frame>5 years</time_frame>
    <description>Primary tumor of distant metastasis should be histopathologically evalueted by taking biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life during follow-up endoscopies (questionnaires)</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life is assessed by using questionnaires on set time points during the whole study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">141</enrollment>
  <condition>Submucosal Esophageal Adenocarcinoma</condition>
  <condition>Barrett Esophagus</condition>
  <arm_group>
    <arm_group_label>Endoscopic follow-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with endoscopic resection (ER) for a submucosal esophageal adenocarcinoma without lymphnode- or distant metastases (T1bN0M0 EAC) will undergo endoscopic follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic follow-up</intervention_name>
    <description>Endoscopic follow-up by means of regular upper endoscopies and endoscopic ultrasounds</description>
    <arm_group_label>Endoscopic follow-up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with submucosal EAC diagnosed in an ER specimen, revised by a panel of expert
             gastrointestinal (GI) pathologists.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Prior history of esophageal cancer â‰¥T1sm.

          -  Synchronous esophageal squamous cell carcinoma.

          -  Suspicion on lymph node metastasis or distant metastasis on EUS, ultrasound of the
             neck or CT-thorax-abdomen performed six weeks after ER during baseline measurement.

          -  Tumor-positive deep resection margin (R1) in ER specimen.

          -  Patients unable to give signed informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. J. Bergman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. E. Pouw, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>E. Nieuwenhuis, MD</last_name>
    <phone>+31205661613</phone>
    <email>e.a.nieuwenhuis@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>W. D. Rosmolen, Master</last_name>
    <phone>+31205663252</phone>
    <email>w.d.rosmolen@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Westmead hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Bourke, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Bisschops, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>R. Bisschops, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>H. Messmann</last_name>
      <email>Helmut.Messmann@uk-augsburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E. Nieuwenhuis, MD</last_name>
      <phone>+31205661613</phone>
      <email>e.a.nieuwenhuis@amsterdamumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>W. D. Rosmolen, Master</last_name>
      <phone>+31205663252</phone>
      <email>w.d.rosmolen@amsterdamumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>J. J. Bergman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>R. E. Pouw, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VuMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E. Nieuwenhuis, MD</last_name>
      <phone>+31645916097</phone>
      <email>e.a.nieuwenhuis@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E. J. Schoon, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>E. J. Schoon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. B. Nagengast, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>W. B. Nagengast, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. L. Weusten, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>B. L. Weusten, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. Siersema, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC - University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. D. Koch, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>A. D. Koch, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haga Medical Center</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Houben, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>M. Houben, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Clinics</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B. E. Schenk, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>B. E. Schenk, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirslanden private hospital group</name>
      <address>
        <city>ZÃ¼rich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Seewald</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>R. Haidry, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>R. Haidry, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>prof. dr. J.J.G.H.M. Bergman</investigator_full_name>
    <investigator_title>Professor of Gastrointestinal Endoscopy</investigator_title>
  </responsible_party>
  <keyword>Barrett's esophagus</keyword>
  <keyword>Submucosal esophageal adenocarcinoma</keyword>
  <keyword>Endoscopic treatment</keyword>
  <keyword>Endoscopic follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

